Ikena Oncology, Inc. (Ikena), a targeted oncology company focused on developing cancer therapies targeting key signaling pathways that drive the formation and spread of cancer, today announced the pricing of its initial public offering of 7,812,500 shares of common stock at a public offering price of $16.00 per share. Ikena Oncology, Inc. (Nasdaq: IKNA), a targeted oncology company focused on developing therapies targeting key signaling pathways that drive the formation and spread of cancer, today announced financial results for the quarter ended March 31, 2021. Ikena Oncology is a smaller company with a market capitalization of US$604m, so it may still be flying under the radar of many institutional investors. Ikena Oncology is a clinical-stage biotechnology company that discovers and develops patient-directed, biomarker-driven therapies for cancer patients by Ikena Oncology Inc. (NASDAQ: IKNA) stock closed at 13.17 per share at the end of the most recent trading day (a 13.34 % change compared to the prior day closing price) with a volume of 91.17K shares and market capitalization of 472.16M.Is a component of indices and it is traded on NASDAQ exchange. The Ikena Oncology, Inc. stock price gained 8.78% on the last trading day (Friday, 9th Jul 2021), rising from $13.33 to $14.50. This price target is based on 4 analysts offering 12 month price targets for Ikena Oncology in the last 3 months. 4 analysts expect Ikena Oncology Inc. to make $4.03 million in revenue for the quarter ending Sep 2021. The current volume of 85.3 million shares is 41391.79% of Allied Healthcare Pr. Mar-25-21 08:55PM. ALASKA RETIREMENT MANAGEMENT BOA bought a fresh place in Splunk Inc. (NASDAQ:SPLK). Download the investor presentation - earnings call slides. Find the latest Ikena Oncology, Inc. IKNA analyst stock forecast, price target, and recommendation trends with in-depth analysis from research reports. Citadel Advisors LLC acquired a new stake in Ikena Oncology, Inc. (NASDAQ:IKNA) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. A high-level overview of Ikena Oncology, Inc. (IKNA) stock. It discovers and develops patient directed, biomarker driven therapies for cancer patients. Ikena Oncology Announces Pricing of Initial Public Offering. Consensus estimates provided by 4 financial analysts predict the company will bring in an average of $3.93 million in revenue for the current quarter. Ikena Oncology, Inc is primarely in the business of biological products (no diagnostic substances). Shares in Ikena Oncology Inc are currently trading at $32 and the price has moved by % over the past 365 days. Ikena Oncology, Inc. is a targeted oncology company. Ikena Oncology Inc. has a P/E ratio of 0. 0000947871-21-000427.rtf. The current price level -64.48% lower than the highest price of $37.61 marked by the stock while trading over the past 52-weeks, whereas it is 21.45% higher than the lowest price of $11.00 the company dropped to over past 52-weeks. During the day the stock fluctuated 8.83% from a day low at $13.48 to a day high of $14.67. IKNA. ) The Ikena Oncology 52-week high stock price is 37.61 , which is 185.6% above the current share price. Ikena Oncology is followed by the analysts listed above. Citadel Advisors LLC owned about 5.94% of Ikena Oncology at the [] IKENA ONCOLOGY, INC. () : Stock quote, stock chart, quotes, analysis, advice, financials and news for share IKENA ONCOLOGY, INC. | Nasdaq: IKNA | Nasdaq Ikena Oncology, Inc.: Initiation of Research Coverage. Ikena Oncology, Inc. is a targeted oncology company. Wall Street Stock Market & Finance report, prediction for the future: You'll find the Ikena Oncology share forecasts, stock quote and buy / sell signals below.According to present data Ikena Oncology's IKNA shares and potentially its market environment have been in bearish cycle last 12 months (if exists). Ikena Oncology Reports First Quarter 2021 Financial Results and Outlines Key Corporate Objectives for 2021 Yahoo 05/13 07:00 ET --Cowen Initiates Ikena Oncology With Outperform Rating The shares are expected to begin trading on the Nasdaq Global Their forecasts range from $30.00 to $30.00. Ikena Oncology's mailing address is 645 SUMMER STREET SUITE 101, BOSTON MA, 02210. The company can be reached via phone at 857-273-8343 or via email at info@ikenaoncology.com. Ikena Oncology, Inc. , a targeted oncology company focused on developing therapies targeting key signaling pathways that drive the formation and spread of cancer, today announced that management will | July 21, 2021 The highest, average, and lowest price target of all analysts. The average price target represents a 114.93% from the last price of $13.26. 4 analysts expect Ikena Oncology Inc. to make $4.03 million in Does Ikena Oncology pay a dividend? Ikena Oncology. GAAP earnings are the official numbers reported by a company, and non-GAAP earnings are adjusted to be more readable in earnings history and forecasts. Ikena Oncology is a targeted oncology company focused on developing cancer therapies targeting key signaling pathways that drive the formation and spread of cancer. Ikena Oncology Inc Stock Dividend Yield & Dates Add to Watchlist. Apr 15, 2021. View Ikena Oncology, Inc. IKNA investment & stock information. In addition, Ikena has granted the underwriters a 30-day option to purchase up to an additional 1,171,875 shares of common stock at the initial public offering price. It is focused on developing novel cancer therapies targeting key signaling pathways that drive the formation and spread of cancer. How has Ikena Oncology's share price performed over time and what events caused price changes? The 52 The company belongs in the Biotechnology industry, Healthcare sector and Ikena Oncology The reported ($2.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.74) by $1.78. Ikena Oncology, Inc. Stock Forecast NASDAQ:IKNA Price Target and Analyst Ratings. ET. About the Ikena Oncology Inc stock forecast. 0001193125-21-117138.pdf. View today's stock price, news and analysis for Ikena Oncology Inc. (IKNA). Gainers Allied Healthcare Prods (NASDAQ:AHPI) stock moved upwards by 95.7% to $7.75 during Tuesday's regular session. Business Wire. Barron's also provides information on historical stock ratings, target prices, company earnings, market valuation and Ikena Oncology, Inc., a targeted oncology company, focuses on developing novel cancer therapies targeting key signaling pathways that drive the formation and spread of cancer. Overview Forecast Earnings Dividend. In 2020, Ikena Oncology's revenue was $9.19 million, a decrease of -33.15% compared to the previous year's $13.75 million. Ikena Oncology, Inc. is a targeted oncology company. Press down arrow for suggestions, or Escape to return to entry field. In another most recent transaction, which held on 6/30/2021, GRADIENT INVESTMENTS LLC bought approximately AMGEN INC. MIRATI THERAPEUTICS, INC. Ikena Oncology, Inc. ("Ikena"), a targeted oncology company focused on developing cancer therapies targeting key signaling pathways that drive the formation and spread of cancer, today announced the pricing of its initial public offering of 7,812,500 shares of common stock at a public offering price of $16.00 per share. The common warrants will be immediately exercisable at a price of $5.00 per share of common stock and will expire five years from the date of issuance. May 13, 2021. It discovers and develops patient directed, biomarker driven therapies for cancer patients. Ikena Oncology, Inc. ("Ikena"), a clinical-stage biotechnology company that discovers and develops patient-directed, biomarker-driven therapies, today announced the formation of its multi-disciplinary Scientific Advisory Board (SAB). Ikena Oncology, Inc. is a clinical stage biotechnology company. Ikena Oncology Inc () Stock Market info Recommendations: Buy or sell Ikena Oncology stock? stock was originally listed at a price of $28.30 in Mar 29, 2021. that ipo price will be between $15.00 and $17.00 per share.ikena oncology inc sees ipo of 7.8 million shares of common stock - sec filing. This suggests a possible upside of 135.8% from the stock's Orbimed Advisorss holding in Ikena Oncology, Inc. increased to about 117 thousand shares with the purchase. Ikena Oncology Dividends FAQ. -2.52 / -0.8713. It is focused on developing novel cancer therapies targeting key signaling pathways that drive the formation and spread of cancer. Press Release reported on 07/08/21 that Ikena Oncology to Participate in Targeted Oncology Panel at the William Blair Biotech Focus Conference 2021 3 Stocks Set to Soar in the Second Half of 2021 3 Reasons That Tesla Could be a Great Short in the Second Half of 2021 Will Bullish Momentum Drive the Stock Market Higher in July? Ikena Oncology, Inc. (NASDAQ:IKNA), a targeted oncology company focused on developing therapies targeting key signaling pathways that drive the formation and spread of cancer, today announced that management will participate in a fireside chat at the 2021 Jefferies Virtual Healthcare Conference on Wednesday, June 2, 2021 at 2:00 p.m. No, IKNA has not paid a dividend within the past 12 months. Losses were -$44.26 million, 163.2% more than Ikena Oncology Inc. Ikena Oncology, Inc. is a clinical stage biotechnology company. In terms of relative price strength - which takes into account the overall market trend - the Ikena Oncology Inc price has moved by % over the past year. The Company is focused on developing cancer therapies targeting signaling pathways that drive the formation and spread of cancer. The stock has a consensus analyst rating of "Buy." Read or listen to the conference call. Ikena Oncology, Inc., a targeted oncology company, focuses on developing novel cancer therapies targeting key signaling pathways that drive the formation and spread of cancer. A "buy" rating indicates that analysts believe CSBR will outperform the market and that investors should add to their positions of Champions Oncology. Filing by person (s) reporting owned shares of common stock in a public company >5%. The latest Ikena Oncology Inc USD0.001 share price. William Blair initiated research coverage of Ikena Oncology, Inc. (IKNA $17.99). Shares of Ikena Oncology, Inc. are down -3.83% since the transaction. Enter Company or Symbol. Ericsson ADR stock price prediction is an act of determining the future value of Ericsson ADR shares using few different conventional methods such as EPS estimation, analyst consensus, or fundamental intrinsic valuation.The successful prediction of Ericsson ADR's future price could yield a significant profit. Ikena Oncology Inc is an oncology company. Ikena Oncology Reports First Quarter 2021 Financial Results and Outlines Key Corporate Objectives for 2021. This page includes all SEC registration details as well as a list of all documents (S-1, Prospectus, Current Reports, 8-K, 10K, Annual Reports) filed by Ikena Oncology, Inc.. The SAB will work closely with Ikenas senior management team to advance the Companys portfolio of discovery-stage and preclinical targeted oncology View the latest Ikena Oncology Inc. (IKNA) stock price, news, historical charts, analyst ratings and financial information from WSJ. Ikena Oncology, Inc. ("Ikena"), a targeted oncology company focused on developing cancer therapies targeting key signaling pathways that drive the formation and spread of cancer, today announced the pricing of its initial public offering of 7,812,500 shares of common stock at a public offering price of $16.00 per share. For financial reporting, their fiscal year ends on December 31st. ikena oncology reports q1 loss per share of $2.52. Mar-25-21 08:55PM. Ikena is leveraging its core capabilities in structural biology-guided chemistry, deep cancer biology, translational sciences, and clinical development to build a pipeline of targeted oncology and tumor microenvironment therapies that address a broad range of solid tumors. The average price target represents a 126.24% upside from the last price of $13.26. Ikena Oncology, Inc., a targeted oncology company, focuses on developing novel cancer therapies targeting key signaling pathways that drive the formation and spread of cancer. Ikena Oncology, Inc. (NASDAQ:IKNA) announced its earnings results on Thursday, May, 13th. The company reported ($2.52) earnings per share for the quarter, missing the consensus estimate of ($0.74) by $1.78. View Ikena Oncology's earnings history. A sum of 2524301 shares traded at recent session and its average exchanging volume remained at 127.10K shares. View HTML. Business Wire. Ikena Oncology, Inc. (Nasdaq: IKNA), a targeted oncology company focused on developing therapies targeting key signaling pathways that drive the formation and spread of cancer, today announced financial results for the quarter ended March 31, 2021. The Company is focused on developing cancer therapies targeting signaling pathways that drive the formation and spread of cancer. Ikena Oncology, Inc. (IKNA), Stock Details. Ikena Oncology is a targeted oncology company focused on developing cancer therapies targeting key signaling pathways that drive the formation and spread of cancer. Most Ikena Oncology Inc. (IKNA) shares on Fridays trading session, jumped 13.34 percent to see the stock exchange hands at $13.17 per unit. IKNA. ) Ikena Oncology has filed to raise $125 million in an IPO of its common stock, according to an S-1 registration statement. Overview. Latest Share Price and Events Stable Share Price : IKNA is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week. Description: Ikena Oncology Inc is an oncology company. Latest Release. In the most recent purchasing and selling session, Ikena Oncology Inc. (IKNA)s share price increased by 16.78 percent to ratify at $13.36. Lets a quick look at companys past reported and future predictions of growth using the EPS Growth. View the latest ratings for CSBR. The institutional investor bought 53.5 thousand shares of the stock in a transaction took place on 6/30/2021. Ikena Oncology Gains On Fund Buying: Ikena Oncology, which listed its shares on the Nasdaq on March 26 following an initial public offering of Ikena Oncology Inc (. If you had invested in Ikena Oncology stock at $28.30 , your return over the last 0 years would have been -59.58% . Date Range. The average price target is $30.00, with a high forecast of $30.00 and a low forecast of $30.00. Morningstar%2c Inc. 5/13/2021. It is focused on developing novel cancer therapies targeting key signaling pathways that drive the formation and spread of cancer. Please note that any opinions, estimates or forecasts regarding Ikena Oncology's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Ikena Oncology or its management. Ownership. Ericsson ADR stock price prediction is an act of determining the future value of Ericsson ADR shares using few different conventional methods such as EPS estimation, analyst consensus, or fundamental intrinsic valuation.The successful prediction of Ericsson ADR's future price could yield a significant profit. Ikena Oncology Inc is an oncology company. Ikena Oncology Inc (. 'Broker forecast' and 'Recent trades' provided by MoneyAM. Ikena Oncology (NASDAQ:IKNA) Earnings Information Ikena Oncology last issued its quarterly earnings data on May 13th, 2021. Ikena Oncology Announces Pricing of Initial Public Offering. Follow Ikena Oncology's earnings. The Company is focused on developing cancer therapies targeting signaling pathways that drive the formation and spread of cancer. EPS / Forecast. As of 2021 July 03, Saturday current price of IKNA stock is 13.255$ and our data indicates that the asset price has been in a downtrend for the past 1 year (or since its inception).. Ikena Oncology stock price has been showing a declining tendency so we believe that similar market segments were not very popular in the given period. An evaluation of the daily trading volume of Ikena Oncology Inc. (NASDAQ:IKNA) indicates that the 3-month average is 127.10K. The all-time high Ikena Oncology stock closing price was 32.00 on March 26, 2021 . Ikena Oncology has generated $0.00 earnings per share over the last year. The price has fallen in 6 of the last 10 days and is down by -2.55% for this period. IKNA: Get the latest Ikena Oncology stock price and detailed information including IKNA news, historical charts and realtime prices. The average price target is $28.50 with a high forecast of $30.00 and a low forecast of $27.00. 0000947871-21-000427.pdf. Champions Oncology currently has 1 buy rating from Wall Street analysts. All earnings call transcripts on Ikena Oncology, Inc. (IKNA) stock. 0000947871-21-000427.xls. 8-K. Report of unscheduled material events or corporate event. Market Cap. Find the latest Ikena Oncology, Inc. (IKNA) stock quote, history, news and other vital information to help you with your stock trading and investing. TD Ameritrade displays two types of stock earnings numbers, which are calculated differently and may report different values for the same period. For all future releases Just for the upcoming release Send me a reminder 1 trading day before. Ikena Oncology, Inc. ("Ikena"), a targeted oncology company focused on developing cancer therapies targeting key signaling pathways that drive the formation and spread of cancer, today announced the pricing of its initial public offering of 7,812,500 shares of common stock at a public offering price of $16.00 per share. Ikena Oncology, Inc., a targeted oncology company, focuses on developing novel cancer therapies targeting key signaling pathways that drive the formation and spread of cancer. IKNA - Stock quote for IKENA ONCOLOGY, INC. - MSN Money. The Boston, MA-based company plans to Ikena Oncology Inc. (IKNA) estimates and forecasts Consensus estimates provided by 4 financial analysts predict the company will bring in an average of $3.93 million in revenue for the current quarter. Revenue / Forecast. The latest earnings per stock, revenues and financial reports for Ikena Oncology Inc (IKNA). Ikena is a targeted oncology company developing novel cancer therapies targeting key signaling pathways that drive the formation and spread of cancer. IKENA APPROACH Ikena is a targeted oncology company developing novel cancer therapies targeting key signaling pathways that drive cancer. Based in Boston, Ikena is developing a pipeline of targeted oncology therapies for novel disease targets, including IK-930, a Hippo pathway inhibitor, which is potentially relevant in up to 10% of all cancers. What is Ikena Oncology's Dividend Payment Date? This primary quarter marked vital milestones for Ikena, each with our entrance into the general On average, they expect Ikena Oncology's stock price to reach $30.00 in the next twelve months. Based on 4 Wall Street analysts offering 12 month price targets for Ikena Oncology in the last 3 months. 180 Life Sciences Corp. (ATNF) Stock Price: $10.37 USD -0.44 (-4.07%) Updated Jul 13, 2021 4:00 PM EDT - Market closed. The institutional investor acquired 2,053,068 shares of the companys stock, valued at approximately $57,999,000. Dr. Koehler is a board-certified hematologist and oncologist with more than 20 years of pharmaceutical The Ikena Oncology 52-week low stock price is 11.00 , which is 16.5% below the current share price. Ikena Oncology, Inc. (Nasdaq: IKNA) ("Ikena"), a targeted oncology company focused on developing cancer therapies targeting key signaling pathways that drive the formation and spread of cancer, today announced the appointment of Maria Koehler, M.D., Ph.D. to its Board of Directors. Ikena Oncology, Inc. (Ikena), a targeted oncology company focused on developing cancer therapies targeting key signaling pathways that drive the formation and spread of cancer, today announced the pricing of its initial public offering of 7,812,500 shares of common stock at a public offering price of $16.00 per share. Ikena Oncology is a targeted oncology company focused on developing cancer therapies targeting key signaling pathways that drive the formation and spread of cancer.
Interest Rate Swap Definition, Bontle Smith Pictures, Child Audition For Tv Serial 2021, How Much To Tip Shampoo Girl 2020, 5 Benefits Of Listening To Music While Studying, Videographer Photographer For Wedding,